On May 22, 2025 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will present two-year disease-free survival (DFS) data from all patients in the randomized Phase I part of the trial of its individualized neoantigen therapeutic cancer vaccine TG4050 (Press release, Transgene, MAY 22, 2025, View Source [SID1234653325]). The data will be shared during a rapid oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago from May 30 to June 3, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TG4050 is a viral vector-based immunotherapy based on Transgene’s myvac platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen selection.
TG4050 is being evaluated in a randomized multicenter Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Based on promising Phase I data, Transgene and partner NEC have advanced the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.
Key data to be presented include:
Safety in locally advanced HPV-negative resectable head and neck squamous cell carcinoma (HNSCC),
Disease free survival after 2-year follow-up,
Updated immunogenicity data.
Prof. Le Tourneau, MD, PhD, Head of the Department of Drug Development and Innovation (D3i) at Institut Curie, and Principal Investigator commented: "It is a privilege to present these study data which are based on the highly promising myvac platform for individualized cancer vaccines. This oral presentation at ASCO (Free ASCO Whitepaper) offers an opportunity to highlight both the strength of the clinical data and the collaborative efforts of everyone involved in the trial."
Dr. Emmanuelle Dochy, MD, Chief Medical Officer of Transgene, added: "We are pleased to have our latest findings on TG4050 selected for presentation among so many high-quality submissions to ASCO (Free ASCO Whitepaper). This recognition reflects the dedication of our teams and the significance of our work in advancing medical science and patient care for those suffering from cancer. The Phase II part of our trial is currently enrolling patients internationally, as we continue to evaluate TG4050’s potential in this setting."
The rapid oral presentation will take place on June 1st at 1:30 p.m. CDT during ASCO (Free ASCO Whitepaper) 2025 and will also be available to view on Transgene’s website.
In addition, Transgene will present a poster at ASCO (Free ASCO Whitepaper) on TG4001, presenting randomized Phase II data in combination with avelumab in a cervical cancer subgroup. Following the previously reported topline results from this study in the overall patient population (see press release here), Transgene is currently evaluating potential partnership opportunities to determine the best path forward for the program.